Two Sigma Investments’s VYNE Therapeutics VYNE Stock Holding History

Two Sigma Investments’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255K	Buy	426,412 +206,412	+94%	+$120K	﹤0.01%	4167
2025 Q4	$128K	Sell	220,000 -788	-0.4%	-$316	﹤0.01%	3835
2025 Q3	$74K	Buy	+220,788	New	+$144K	﹤0.01%	3507
2021 Q4	–	Sell	-4,516	Closed	-$113K	–	4941
2021 Q3	$113K	Buy	4,516 +1,903	+73%	+$73.8K	﹤0.01%	4071
2021 Q2	$165K	Sell	2,613 -13,936	-84%	-$1.1M	﹤0.01%	3831
2021 Q1	$2.04M	Buy	16,549 +3,719	+29%	+$539K	0.01%	1694
2020 Q4	$1.46M	Buy	12,830 +8,316	+184%	+$1.05M	﹤0.01%	1717
2020 Q3	$540K	Sell	4,514 -2,492	-36%	-$291K	﹤0.01%	2187
2020 Q2	$873K	Buy	+7,006	New	+$949K	﹤0.01%	1624
2019 Q3	–	Sell	-362	Closed	-$156K	–	3834
2019 Q2	$156K	Buy	362 +212	+141%	+$105K	﹤0.01%	3135
2019 Q1	$85K	Sell	150 -429	-74%	-$206K	﹤0.01%	2912
2018 Q4	$172K	Sell	579 -973	-63%	-$436K	﹤0.01%	2743
2018 Q3	$1.1M	Buy	+1,552	New	+$958K	﹤0.01%	1905

Other funds holding VYNE

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

T3 Companies New York $76.8M AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $134M AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments's VYNE Position: Q1 2026 in Review

Two Sigma Investments increased its VYNE Therapeutics (VYNE) stake by 94% in Q1 2026, buying an estimated $120K and bringing the position to 426,412 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #4167.

Two Sigma Investments first reported a position in VYNE in Q3 2018 and has held it in 13 quarters since. The position peaked at $2.04M in Q1 2021. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

Two Sigma Investments held 426,412 shares of VYNE Therapeutics worth $255K as of Q1 2026.
Two Sigma Investments bought 206,412 VYNE Therapeutics shares in Q1 2026, an estimated $120K.
VYNE Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4167 holding.
Two Sigma Investments first reported a position in VYNE Therapeutics in Q3 2018 and has held it in 13 quarters since.
Two Sigma Investments's VYNE Therapeutics position peaked at $2.04M in Q1 2021.
45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.